Barclays Reiterates Overweight Rating on Madrigal Pharmaceuticals, Inc. (MDGL)
Rating Change Barclays analysts reiterated a Overweight rating on Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) on August 03, 2026. Market Context Madrigal Pharmaceuticals, Inc.
Read more
